Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Stroke | 16 | 2024 | 966 | 2.560 |
Why?
|
Neurology | 10 | 2016 | 71 | 2.000 |
Why?
|
Ischemic Attack, Transient | 6 | 2023 | 182 | 1.960 |
Why?
|
Receptors, AMPA | 11 | 2009 | 66 | 1.510 |
Why?
|
Clinical Clerkship | 8 | 2016 | 117 | 1.490 |
Why?
|
Brain Ischemia | 6 | 2023 | 402 | 1.160 |
Why?
|
Calcium | 16 | 2007 | 1170 | 1.150 |
Why?
|
Cerebral Small Vessel Diseases | 2 | 2024 | 8 | 1.090 |
Why?
|
Neurons | 19 | 2011 | 1563 | 1.050 |
Why?
|
Clinical Competence | 4 | 2015 | 777 | 0.810 |
Why?
|
Arterial Occlusive Diseases | 2 | 2023 | 107 | 0.800 |
Why?
|
Glutamic Acid | 8 | 2007 | 154 | 0.800 |
Why?
|
Students, Medical | 4 | 2015 | 409 | 0.780 |
Why?
|
Education, Medical, Undergraduate | 4 | 2016 | 169 | 0.770 |
Why?
|
Platelet Aggregation Inhibitors | 5 | 2023 | 138 | 0.760 |
Why?
|
Foramen Ovale, Patent | 1 | 2021 | 18 | 0.750 |
Why?
|
Nonlinear Dynamics | 1 | 2021 | 73 | 0.750 |
Why?
|
Neurologic Examination | 2 | 2020 | 119 | 0.690 |
Why?
|
Motor Neurons | 4 | 2001 | 168 | 0.690 |
Why?
|
Stroke, Lacunar | 2 | 2018 | 4 | 0.670 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2022 | 376 | 0.620 |
Why?
|
Reperfusion Injury | 2 | 2011 | 139 | 0.620 |
Why?
|
Hypertension | 1 | 2024 | 722 | 0.620 |
Why?
|
Intracranial Embolism | 1 | 2018 | 29 | 0.600 |
Why?
|
Brain | 5 | 2024 | 2254 | 0.600 |
Why?
|
Aspirin | 4 | 2023 | 157 | 0.570 |
Why?
|
Kainic Acid | 8 | 2001 | 22 | 0.560 |
Why?
|
Computed Tomography Angiography | 1 | 2018 | 135 | 0.560 |
Why?
|
Magnetic Resonance Angiography | 2 | 2018 | 266 | 0.550 |
Why?
|
Purkinje Cells | 6 | 1999 | 81 | 0.530 |
Why?
|
Patient Simulation | 1 | 2015 | 43 | 0.520 |
Why?
|
Statistics as Topic | 2 | 2015 | 235 | 0.520 |
Why?
|
Heart Diseases | 1 | 2018 | 294 | 0.510 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2024 | 1157 | 0.510 |
Why?
|
Cells, Cultured | 21 | 2014 | 2844 | 0.510 |
Why?
|
Cerebral Cortex | 3 | 2011 | 587 | 0.500 |
Why?
|
Hypoxia-Inducible Factor 1, alpha Subunit | 3 | 2014 | 154 | 0.470 |
Why?
|
Intracranial Hemorrhages | 5 | 2023 | 124 | 0.470 |
Why?
|
Inpatients | 4 | 2023 | 307 | 0.460 |
Why?
|
Nerve Degeneration | 4 | 2011 | 83 | 0.460 |
Why?
|
Patch-Clamp Techniques | 9 | 2011 | 396 | 0.450 |
Why?
|
Nitric Oxide | 4 | 2011 | 278 | 0.430 |
Why?
|
Rats | 21 | 2007 | 4022 | 0.430 |
Why?
|
Pyramidal Cells | 3 | 2007 | 81 | 0.430 |
Why?
|
Echocardiography | 1 | 2018 | 932 | 0.430 |
Why?
|
Tunicamycin | 1 | 2012 | 13 | 0.420 |
Why?
|
Inclusion Bodies | 1 | 2012 | 34 | 0.420 |
Why?
|
Cerebellum | 7 | 2014 | 249 | 0.420 |
Why?
|
Ammonia | 1 | 2011 | 38 | 0.410 |
Why?
|
Hyperammonemia | 1 | 2011 | 12 | 0.410 |
Why?
|
Brain Edema | 1 | 2011 | 50 | 0.400 |
Why?
|
Hepatic Encephalopathy | 1 | 2011 | 43 | 0.400 |
Why?
|
Drug Therapy, Combination | 2 | 2023 | 795 | 0.380 |
Why?
|
Recurrence | 5 | 2022 | 1168 | 0.380 |
Why?
|
Spinal Cord | 3 | 2001 | 250 | 0.380 |
Why?
|
Educational Measurement | 1 | 2012 | 230 | 0.370 |
Why?
|
Thrombectomy | 5 | 2024 | 168 | 0.360 |
Why?
|
Rats, Sprague-Dawley | 9 | 2007 | 1226 | 0.350 |
Why?
|
Receptors, Glutamate | 3 | 2007 | 24 | 0.350 |
Why?
|
Humans | 36 | 2024 | 87949 | 0.340 |
Why?
|
Animals | 32 | 2014 | 27028 | 0.320 |
Why?
|
Cell Survival | 7 | 2011 | 977 | 0.310 |
Why?
|
S-Nitrosothiols | 2 | 1997 | 5 | 0.300 |
Why?
|
Endovascular Procedures | 2 | 2023 | 249 | 0.300 |
Why?
|
Hypoxia | 2 | 2011 | 649 | 0.300 |
Why?
|
DNA-Binding Proteins | 2 | 2012 | 1224 | 0.300 |
Why?
|
Intracranial Thrombosis | 2 | 2020 | 27 | 0.300 |
Why?
|
Hippocampus | 4 | 1999 | 446 | 0.280 |
Why?
|
Hypoxia-Ischemia, Brain | 1 | 2007 | 53 | 0.280 |
Why?
|
Organ Culture Techniques | 3 | 2012 | 135 | 0.270 |
Why?
|
Receptors, N-Methyl-D-Aspartate | 6 | 2008 | 87 | 0.260 |
Why?
|
Fluorescent Dyes | 2 | 2004 | 243 | 0.260 |
Why?
|
Emergency Service, Hospital | 2 | 2020 | 498 | 0.260 |
Why?
|
Ambulatory Care Facilities | 2 | 2016 | 111 | 0.250 |
Why?
|
alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid | 4 | 2000 | 10 | 0.250 |
Why?
|
Motor Cortex | 1 | 2007 | 196 | 0.250 |
Why?
|
Cell Hypoxia | 1 | 2005 | 170 | 0.250 |
Why?
|
Pyramidal Tracts | 1 | 2004 | 16 | 0.250 |
Why?
|
Animals, Newborn | 4 | 2012 | 519 | 0.240 |
Why?
|
Staining and Labeling | 1 | 2004 | 167 | 0.230 |
Why?
|
Glucose | 2 | 2022 | 628 | 0.230 |
Why?
|
Thrombolytic Therapy | 3 | 2023 | 225 | 0.230 |
Why?
|
Calcium Channels | 3 | 2001 | 182 | 0.230 |
Why?
|
Cerebral Infarction | 1 | 2023 | 72 | 0.220 |
Why?
|
Risk Factors | 6 | 2021 | 5405 | 0.220 |
Why?
|
Blotting, Western | 4 | 2014 | 794 | 0.220 |
Why?
|
Basilar Artery | 3 | 2023 | 41 | 0.220 |
Why?
|
Retrospective Studies | 10 | 2024 | 8780 | 0.220 |
Why?
|
Cardiac Catheterization | 2 | 2021 | 297 | 0.220 |
Why?
|
Predictive Value of Tests | 3 | 2020 | 1697 | 0.220 |
Why?
|
Intracranial Arteriosclerosis | 1 | 2023 | 53 | 0.220 |
Why?
|
Amyotrophic Lateral Sclerosis | 2 | 2001 | 187 | 0.220 |
Why?
|
Embolization, Therapeutic | 2 | 2024 | 251 | 0.210 |
Why?
|
Treatment Outcome | 9 | 2024 | 8104 | 0.210 |
Why?
|
Mice | 11 | 2014 | 11619 | 0.210 |
Why?
|
Mice, Inbred C57BL | 4 | 2012 | 3169 | 0.210 |
Why?
|
Kinetics | 4 | 2021 | 1528 | 0.200 |
Why?
|
Time Factors | 8 | 2020 | 5284 | 0.200 |
Why?
|
Chicago | 4 | 2020 | 1397 | 0.200 |
Why?
|
Cell Death | 4 | 2007 | 261 | 0.190 |
Why?
|
Septal Occluder Device | 1 | 2021 | 42 | 0.190 |
Why?
|
Calcium Signaling | 1 | 2001 | 138 | 0.180 |
Why?
|
Homeostasis | 3 | 1997 | 406 | 0.180 |
Why?
|
Reproducibility of Results | 3 | 2020 | 2740 | 0.180 |
Why?
|
Cysteine | 2 | 1997 | 136 | 0.180 |
Why?
|
Double-Blind Method | 2 | 2021 | 1711 | 0.180 |
Why?
|
Secondary Prevention | 1 | 2020 | 162 | 0.180 |
Why?
|
Carotid Artery Diseases | 1 | 2020 | 98 | 0.170 |
Why?
|
Excitatory Amino Acid Agonists | 3 | 2007 | 45 | 0.170 |
Why?
|
Fibrinolytic Agents | 1 | 2021 | 208 | 0.160 |
Why?
|
Aged | 10 | 2024 | 18750 | 0.160 |
Why?
|
Decision Support Techniques | 1 | 2020 | 165 | 0.160 |
Why?
|
Health Status Disparities | 1 | 2020 | 175 | 0.160 |
Why?
|
Neural Inhibition | 1 | 1999 | 97 | 0.160 |
Why?
|
Middle Aged | 11 | 2024 | 25477 | 0.160 |
Why?
|
Male | 17 | 2024 | 41697 | 0.150 |
Why?
|
Vertebrobasilar Insufficiency | 1 | 2017 | 16 | 0.150 |
Why?
|
Prognosis | 4 | 2020 | 3729 | 0.150 |
Why?
|
Cerebral Hemorrhage | 1 | 2020 | 334 | 0.150 |
Why?
|
N-Methylaspartate | 3 | 2007 | 51 | 0.150 |
Why?
|
Independent Living | 1 | 2017 | 20 | 0.150 |
Why?
|
Neurotoxins | 3 | 2007 | 49 | 0.150 |
Why?
|
Female | 16 | 2024 | 45399 | 0.150 |
Why?
|
Receptors, Kainic Acid | 2 | 1994 | 13 | 0.140 |
Why?
|
Neurosciences | 2 | 2015 | 52 | 0.140 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2021 | 834 | 0.140 |
Why?
|
Energy Metabolism | 1 | 1999 | 277 | 0.140 |
Why?
|
Membrane Potentials | 5 | 2000 | 436 | 0.140 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 3 | 2005 | 888 | 0.130 |
Why?
|
Hemolysis | 1 | 1995 | 64 | 0.130 |
Why?
|
Embryo, Mammalian | 4 | 2010 | 222 | 0.130 |
Why?
|
Intracellular Membranes | 2 | 1995 | 117 | 0.130 |
Why?
|
Receptors, Neurotransmitter | 2 | 1992 | 26 | 0.130 |
Why?
|
Cytosol | 1 | 1995 | 190 | 0.130 |
Why?
|
Diffusion Magnetic Resonance Imaging | 1 | 2018 | 303 | 0.130 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 317 | 0.130 |
Why?
|
Coronavirus Infections | 1 | 2020 | 302 | 0.130 |
Why?
|
Mitochondria | 1 | 1999 | 545 | 0.130 |
Why?
|
Transcription, Genetic | 1 | 1999 | 1144 | 0.120 |
Why?
|
Calpain | 1 | 1995 | 113 | 0.120 |
Why?
|
Muscle, Smooth, Vascular | 1 | 1995 | 241 | 0.120 |
Why?
|
Paresthesia | 1 | 2014 | 16 | 0.120 |
Why?
|
Outpatient Clinics, Hospital | 1 | 2014 | 23 | 0.120 |
Why?
|
Dizziness | 1 | 2014 | 26 | 0.120 |
Why?
|
Specialty Boards | 1 | 2014 | 24 | 0.120 |
Why?
|
Ataxia | 1 | 2014 | 39 | 0.120 |
Why?
|
Analysis of Variance | 2 | 2011 | 901 | 0.120 |
Why?
|
Hypoxia, Brain | 1 | 2014 | 41 | 0.110 |
Why?
|
Amyloid beta-Peptides | 1 | 1995 | 204 | 0.110 |
Why?
|
Medical Records | 1 | 2014 | 121 | 0.110 |
Why?
|
RNA, Messenger | 5 | 2010 | 1996 | 0.110 |
Why?
|
Workload | 1 | 2014 | 129 | 0.110 |
Why?
|
Peptide Fragments | 1 | 1995 | 459 | 0.110 |
Why?
|
Research | 1 | 2014 | 250 | 0.110 |
Why?
|
Protein Kinases | 1 | 2014 | 211 | 0.110 |
Why?
|
Education, Medical | 1 | 2016 | 243 | 0.110 |
Why?
|
Phosphoproteins | 1 | 2014 | 258 | 0.110 |
Why?
|
Heart Septal Defects, Atrial | 2 | 2003 | 64 | 0.110 |
Why?
|
Ibotenic Acid | 1 | 1992 | 5 | 0.110 |
Why?
|
TDP-43 Proteinopathies | 1 | 2012 | 8 | 0.100 |
Why?
|
Cell Membrane Permeability | 2 | 2004 | 119 | 0.100 |
Why?
|
Protein Biosynthesis | 1 | 2014 | 389 | 0.100 |
Why?
|
Neuroprotective Agents | 2 | 2007 | 95 | 0.100 |
Why?
|
Protein Isoforms | 2 | 2004 | 273 | 0.100 |
Why?
|
Electrophysiology | 3 | 2007 | 402 | 0.100 |
Why?
|
Curriculum | 1 | 2016 | 556 | 0.100 |
Why?
|
Disease Management | 1 | 2013 | 328 | 0.100 |
Why?
|
Nerve Net | 1 | 1995 | 367 | 0.100 |
Why?
|
Excitatory Amino Acid Antagonists | 2 | 2001 | 79 | 0.090 |
Why?
|
Magnesium | 1 | 1991 | 177 | 0.090 |
Why?
|
Posterior Horn Cells | 2 | 2000 | 8 | 0.090 |
Why?
|
Protein Transport | 1 | 2012 | 417 | 0.090 |
Why?
|
Encephalitis | 1 | 2011 | 104 | 0.090 |
Why?
|
Carrier Proteins | 1 | 2014 | 677 | 0.090 |
Why?
|
Lupus Vasculitis, Central Nervous System | 1 | 2010 | 11 | 0.090 |
Why?
|
Complement C5a | 1 | 2010 | 24 | 0.090 |
Why?
|
Receptor, Anaphylatoxin C5a | 1 | 2010 | 21 | 0.090 |
Why?
|
In Situ Nick-End Labeling | 2 | 2010 | 122 | 0.090 |
Why?
|
Receptors, Complement | 1 | 2009 | 46 | 0.090 |
Why?
|
Neurodegenerative Diseases | 1 | 2009 | 47 | 0.080 |
Why?
|
Synaptic Transmission | 2 | 2004 | 224 | 0.080 |
Why?
|
Attitude of Health Personnel | 1 | 2014 | 642 | 0.080 |
Why?
|
Microscopy, Fluorescence | 2 | 2004 | 427 | 0.080 |
Why?
|
Immunohistochemistry | 4 | 2014 | 1786 | 0.080 |
Why?
|
Osmolar Concentration | 3 | 1997 | 181 | 0.080 |
Why?
|
Lupus Erythematosus, Systemic | 1 | 2009 | 208 | 0.080 |
Why?
|
Gene Expression | 2 | 2004 | 1299 | 0.080 |
Why?
|
Acidosis, Respiratory | 1 | 2007 | 7 | 0.080 |
Why?
|
Disease Models, Animal | 2 | 2011 | 2317 | 0.070 |
Why?
|
Motor Skills | 1 | 2008 | 79 | 0.070 |
Why?
|
Hypercapnia | 1 | 2007 | 44 | 0.070 |
Why?
|
Apoptosis | 3 | 2010 | 1705 | 0.070 |
Why?
|
Riluzole | 1 | 2007 | 15 | 0.070 |
Why?
|
Malonates | 1 | 2007 | 11 | 0.070 |
Why?
|
Sepsis | 1 | 2011 | 313 | 0.070 |
Why?
|
Up-Regulation | 2 | 2010 | 726 | 0.070 |
Why?
|
Necrosis | 1 | 2007 | 208 | 0.070 |
Why?
|
Anti-Bacterial Agents | 1 | 2012 | 765 | 0.070 |
Why?
|
Dimerization | 2 | 2004 | 143 | 0.070 |
Why?
|
Dipeptides | 2 | 1997 | 42 | 0.070 |
Why?
|
Potassium | 1 | 2007 | 252 | 0.070 |
Why?
|
Polymerase Chain Reaction | 3 | 2014 | 927 | 0.070 |
Why?
|
Risk Assessment | 2 | 2020 | 2274 | 0.070 |
Why?
|
Electric Stimulation | 1 | 2007 | 350 | 0.070 |
Why?
|
Cytoskeleton | 1 | 2007 | 194 | 0.070 |
Why?
|
Vascular Endothelial Growth Factor A | 2 | 2005 | 417 | 0.070 |
Why?
|
Rats, Inbred Strains | 2 | 1997 | 312 | 0.060 |
Why?
|
Culture Media, Conditioned | 1 | 2005 | 103 | 0.060 |
Why?
|
Activities of Daily Living | 1 | 2006 | 207 | 0.060 |
Why?
|
Enzymes | 1 | 1985 | 47 | 0.060 |
Why?
|
Cell Line | 2 | 2014 | 2491 | 0.060 |
Why?
|
Axonal Transport | 1 | 2004 | 31 | 0.060 |
Why?
|
Benzoates | 1 | 2004 | 32 | 0.060 |
Why?
|
Oxygen Consumption | 1 | 2005 | 241 | 0.060 |
Why?
|
Microtubule-Associated Proteins | 1 | 2005 | 182 | 0.060 |
Why?
|
Adult | 6 | 2024 | 26131 | 0.060 |
Why?
|
Cell Membrane | 1 | 2007 | 667 | 0.060 |
Why?
|
Radial Artery | 1 | 2024 | 33 | 0.060 |
Why?
|
Stochastic Processes | 1 | 2004 | 77 | 0.060 |
Why?
|
Embolism | 1 | 2003 | 32 | 0.060 |
Why?
|
Benzimidazoles | 1 | 2004 | 113 | 0.060 |
Why?
|
Mutagenesis, Site-Directed | 1 | 2004 | 282 | 0.060 |
Why?
|
Catheters | 1 | 2024 | 76 | 0.060 |
Why?
|
Substrate Specificity | 1 | 2004 | 351 | 0.060 |
Why?
|
Structure-Activity Relationship | 1 | 2004 | 411 | 0.060 |
Why?
|
In Vitro Techniques | 1 | 2004 | 993 | 0.050 |
Why?
|
Embolism, Paradoxical | 1 | 2002 | 2 | 0.050 |
Why?
|
Transfection | 1 | 2004 | 907 | 0.050 |
Why?
|
Fluorometry | 3 | 1997 | 30 | 0.050 |
Why?
|
Education, Medical, Graduate | 2 | 2016 | 384 | 0.050 |
Why?
|
Dizocilpine Maleate | 1 | 2001 | 12 | 0.050 |
Why?
|
Lanthanum | 1 | 2001 | 16 | 0.050 |
Why?
|
Cell Compartmentation | 1 | 2001 | 69 | 0.050 |
Why?
|
Catheters, Indwelling | 1 | 2002 | 112 | 0.050 |
Why?
|
Aged, 80 and over | 2 | 2023 | 6655 | 0.050 |
Why?
|
Benzothiadiazines | 1 | 2000 | 13 | 0.050 |
Why?
|
Action Potentials | 1 | 2004 | 590 | 0.050 |
Why?
|
Receptors, Aryl Hydrocarbon | 1 | 2000 | 16 | 0.050 |
Why?
|
Microscopy, Confocal | 1 | 2001 | 271 | 0.050 |
Why?
|
Benzodiazepines | 1 | 2000 | 65 | 0.050 |
Why?
|
Coculture Techniques | 1 | 2000 | 166 | 0.050 |
Why?
|
Incidence | 2 | 2020 | 1580 | 0.050 |
Why?
|
Mice, Inbred MRL lpr | 2 | 2010 | 36 | 0.040 |
Why?
|
Fetus | 1 | 2001 | 230 | 0.040 |
Why?
|
Hematoma | 1 | 2020 | 106 | 0.040 |
Why?
|
Astrocytes | 1 | 2000 | 141 | 0.040 |
Why?
|
Nitric Oxide Synthase Type II | 2 | 2010 | 86 | 0.040 |
Why?
|
Restriction Mapping | 1 | 1999 | 157 | 0.040 |
Why?
|
Respiratory Therapy | 1 | 2019 | 14 | 0.040 |
Why?
|
Drug Therapy | 1 | 2019 | 70 | 0.040 |
Why?
|
Age Factors | 2 | 2017 | 1853 | 0.040 |
Why?
|
Adolescent | 3 | 2023 | 9111 | 0.040 |
Why?
|
Kidney | 1 | 2004 | 1140 | 0.040 |
Why?
|
Hospitals, University | 1 | 2019 | 195 | 0.040 |
Why?
|
Calcium Channel Blockers | 2 | 1995 | 121 | 0.040 |
Why?
|
Glycolysis | 1 | 1999 | 133 | 0.040 |
Why?
|
S-Nitroso-N-Acetylpenicillamine | 1 | 1997 | 1 | 0.040 |
Why?
|
Molsidomine | 1 | 1997 | 6 | 0.040 |
Why?
|
2-Amino-5-phosphonovalerate | 1 | 1997 | 11 | 0.040 |
Why?
|
6-Cyano-7-nitroquinoxaline-2,3-dione | 1 | 1997 | 14 | 0.040 |
Why?
|
Penicillamine | 1 | 1997 | 12 | 0.040 |
Why?
|
Ecuador | 1 | 2017 | 6 | 0.040 |
Why?
|
Neovascularization, Pathologic | 1 | 2000 | 364 | 0.040 |
Why?
|
Cysteine Proteinase Inhibitors | 1 | 1997 | 53 | 0.040 |
Why?
|
Adenosine Triphosphate | 1 | 1999 | 314 | 0.040 |
Why?
|
Rural Health | 1 | 2017 | 21 | 0.040 |
Why?
|
Leukoencephalopathies | 1 | 2017 | 16 | 0.040 |
Why?
|
Clinical Decision-Making | 1 | 2020 | 268 | 0.040 |
Why?
|
Feasibility Studies | 1 | 2020 | 769 | 0.040 |
Why?
|
Dilatation, Pathologic | 1 | 2017 | 55 | 0.040 |
Why?
|
Free Radical Scavengers | 1 | 1997 | 59 | 0.040 |
Why?
|
Ganglia, Spinal | 3 | 1994 | 73 | 0.040 |
Why?
|
Sex Factors | 1 | 2020 | 1059 | 0.040 |
Why?
|
Hemoglobins | 1 | 1997 | 189 | 0.040 |
Why?
|
Models, Biological | 1 | 2004 | 1759 | 0.040 |
Why?
|
Cerebral Angiography | 1 | 2017 | 197 | 0.040 |
Why?
|
Comorbidity | 1 | 2020 | 941 | 0.040 |
Why?
|
Superoxide Dismutase | 1 | 1997 | 177 | 0.040 |
Why?
|
Benzamides | 1 | 1997 | 236 | 0.040 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2000 | 1939 | 0.030 |
Why?
|
Models, Neurological | 1 | 1999 | 406 | 0.030 |
Why?
|
2,3-Diphosphoglycerate | 1 | 1995 | 4 | 0.030 |
Why?
|
Diphosphoglyceric Acids | 1 | 1995 | 10 | 0.030 |
Why?
|
Pyridoxal Phosphate | 1 | 1995 | 13 | 0.030 |
Why?
|
Suramin | 1 | 1995 | 27 | 0.030 |
Why?
|
Cytoplasm | 1 | 1997 | 284 | 0.030 |
Why?
|
Nitroarginine | 1 | 1995 | 16 | 0.030 |
Why?
|
Amino Acid Oxidoreductases | 1 | 1995 | 9 | 0.030 |
Why?
|
Spectrin | 1 | 1995 | 15 | 0.030 |
Why?
|
Calbindins | 1 | 1995 | 19 | 0.030 |
Why?
|
Nuclear Proteins | 1 | 2000 | 721 | 0.030 |
Why?
|
S100 Calcium Binding Protein G | 1 | 1995 | 22 | 0.030 |
Why?
|
Leucine | 1 | 1995 | 67 | 0.030 |
Why?
|
Nucleotides | 1 | 1995 | 96 | 0.030 |
Why?
|
Carbachol | 1 | 1995 | 36 | 0.030 |
Why?
|
Ambulatory Care | 1 | 2016 | 185 | 0.030 |
Why?
|
Signal Transduction | 3 | 2010 | 3331 | 0.030 |
Why?
|
Arginine | 1 | 1995 | 138 | 0.030 |
Why?
|
Nitric Oxide Synthase | 1 | 1995 | 125 | 0.030 |
Why?
|
Sympathetic Nervous System | 1 | 1995 | 94 | 0.030 |
Why?
|
Capsaicin | 2 | 1993 | 44 | 0.030 |
Why?
|
Enzyme Inhibitors | 1 | 1997 | 642 | 0.030 |
Why?
|
Cycloleucine | 1 | 1994 | 10 | 0.030 |
Why?
|
RNA Cap Analogs | 1 | 2014 | 2 | 0.030 |
Why?
|
Vertebral Artery | 1 | 2014 | 23 | 0.030 |
Why?
|
Eukaryotic Initiation Factors | 1 | 2014 | 8 | 0.030 |
Why?
|
Pandemics | 1 | 2020 | 757 | 0.030 |
Why?
|
Self-Assessment | 1 | 2014 | 46 | 0.030 |
Why?
|
Protein Synthesis Inhibitors | 1 | 2014 | 36 | 0.030 |
Why?
|
Cycloheximide | 1 | 2014 | 56 | 0.030 |
Why?
|
Evoked Potentials | 1 | 1995 | 190 | 0.030 |
Why?
|
Specialization | 1 | 2014 | 65 | 0.030 |
Why?
|
Enzyme Activation | 1 | 1995 | 694 | 0.030 |
Why?
|
Luciferases | 1 | 2014 | 126 | 0.030 |
Why?
|
Neuroglia | 1 | 1994 | 105 | 0.030 |
Why?
|
Glutamates | 1 | 1994 | 89 | 0.030 |
Why?
|
Career Choice | 1 | 2015 | 145 | 0.030 |
Why?
|
China | 1 | 2014 | 230 | 0.030 |
Why?
|
Practice Patterns, Physicians' | 1 | 2019 | 593 | 0.030 |
Why?
|
Hydrogen Peroxide | 1 | 2014 | 159 | 0.030 |
Why?
|
Prevalence | 1 | 2017 | 1247 | 0.030 |
Why?
|
Plasmids | 1 | 2014 | 292 | 0.030 |
Why?
|
DNA, Complementary | 1 | 2014 | 394 | 0.030 |
Why?
|
Dendrites | 1 | 1993 | 100 | 0.030 |
Why?
|
Data Collection | 1 | 2014 | 374 | 0.030 |
Why?
|
Transcription Factors | 1 | 2000 | 1622 | 0.030 |
Why?
|
Nerve Tissue Proteins | 1 | 1995 | 508 | 0.030 |
Why?
|
RNA, Small Interfering | 1 | 2014 | 555 | 0.030 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2014 | 309 | 0.030 |
Why?
|
Cross-Sectional Studies | 1 | 2017 | 1682 | 0.030 |
Why?
|
Gene Expression Regulation | 1 | 2000 | 1956 | 0.020 |
Why?
|
Fluorescent Antibody Technique | 1 | 1992 | 322 | 0.020 |
Why?
|
Biological Transport | 1 | 1992 | 399 | 0.020 |
Why?
|
Phosphorylation | 1 | 2014 | 1121 | 0.020 |
Why?
|
Cell Cycle Proteins | 1 | 2014 | 396 | 0.020 |
Why?
|
Caffeine | 1 | 1991 | 83 | 0.020 |
Why?
|
Complement System Proteins | 1 | 2011 | 83 | 0.020 |
Why?
|
Blood-Brain Barrier | 1 | 2011 | 73 | 0.020 |
Why?
|
Chemokine CXCL2 | 1 | 2010 | 16 | 0.020 |
Why?
|
Neurotransmitter Agents | 1 | 2011 | 106 | 0.020 |
Why?
|
Annexin A5 | 1 | 2010 | 20 | 0.020 |
Why?
|
Intercellular Adhesion Molecule-1 | 1 | 2010 | 71 | 0.020 |
Why?
|
Inflammation Mediators | 1 | 2011 | 155 | 0.020 |
Why?
|
Gliosis | 1 | 2009 | 35 | 0.020 |
Why?
|
Diagnosis, Differential | 1 | 2014 | 1586 | 0.020 |
Why?
|
Complement Activation | 1 | 2009 | 81 | 0.020 |
Why?
|
Cell Adhesion Molecules | 1 | 2010 | 165 | 0.020 |
Why?
|
Mice, Knockout | 1 | 2014 | 1969 | 0.020 |
Why?
|
Seizures | 1 | 1991 | 306 | 0.020 |
Why?
|
Ion Channel Gating | 1 | 1990 | 324 | 0.020 |
Why?
|
Interferon-gamma | 1 | 2009 | 448 | 0.020 |
Why?
|
Cytokines | 1 | 2011 | 795 | 0.020 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2010 | 695 | 0.020 |
Why?
|
Surveys and Questionnaires | 1 | 2014 | 2574 | 0.020 |
Why?
|
Memory | 1 | 2008 | 223 | 0.020 |
Why?
|
Disability Evaluation | 1 | 2006 | 138 | 0.020 |
Why?
|
Neuronal Plasticity | 1 | 2008 | 189 | 0.020 |
Why?
|
Internship and Residency | 1 | 2015 | 1036 | 0.020 |
Why?
|
Motor Activity | 1 | 2008 | 328 | 0.020 |
Why?
|
Solvents | 1 | 1985 | 96 | 0.020 |
Why?
|
Learning | 1 | 2008 | 283 | 0.020 |
Why?
|
Molecular Structure | 1 | 1985 | 288 | 0.020 |
Why?
|
Mice, Transgenic | 1 | 2008 | 1563 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2014 | 2624 | 0.010 |
Why?
|
Survival Analysis | 1 | 2006 | 1539 | 0.010 |
Why?
|
Binding Sites | 1 | 1985 | 1107 | 0.010 |
Why?
|
United States | 2 | 2006 | 6809 | 0.010 |
Why?
|
Survival Rate | 1 | 2006 | 1877 | 0.010 |
Why?
|
Young Adult | 1 | 2014 | 6151 | 0.010 |
Why?
|
Warfarin | 1 | 2002 | 103 | 0.010 |
Why?
|
Teratocarcinoma | 1 | 2000 | 1 | 0.010 |
Why?
|
Aryl Hydrocarbon Receptor Nuclear Translocator | 1 | 2000 | 8 | 0.010 |
Why?
|
Vascular Endothelial Growth Factors | 1 | 2000 | 56 | 0.010 |
Why?
|
Endothelial Growth Factors | 1 | 2000 | 55 | 0.010 |
Why?
|
Lymphokines | 1 | 2000 | 76 | 0.010 |
Why?
|
PC12 Cells | 1 | 2000 | 115 | 0.010 |
Why?
|
Antibody Specificity | 1 | 2000 | 130 | 0.010 |
Why?
|
Hypoxia-Inducible Factor 1 | 1 | 2000 | 42 | 0.010 |
Why?
|
Sequence Homology, Amino Acid | 1 | 2000 | 416 | 0.010 |
Why?
|
Transcriptional Activation | 1 | 2000 | 286 | 0.010 |
Why?
|
Gene Deletion | 1 | 2000 | 341 | 0.010 |
Why?
|
Stem Cell Transplantation | 1 | 2000 | 187 | 0.010 |
Why?
|
Basic Helix-Loop-Helix Transcription Factors | 1 | 2000 | 168 | 0.010 |
Why?
|
Anticoagulants | 1 | 2002 | 420 | 0.010 |
Why?
|
Mice, Nude | 1 | 2000 | 810 | 0.010 |
Why?
|
Stem Cells | 1 | 2000 | 364 | 0.010 |
Why?
|
Protein Binding | 1 | 2000 | 1476 | 0.010 |
Why?
|
Muscarine | 1 | 1995 | 1 | 0.010 |
Why?
|
Liver | 1 | 2000 | 1235 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2002 | 3650 | 0.010 |
Why?
|
Fura-2 | 1 | 1994 | 22 | 0.010 |
Why?
|
Terpenes | 1 | 1994 | 17 | 0.010 |
Why?
|
Calcium-Transporting ATPases | 1 | 1994 | 29 | 0.010 |
Why?
|
Thapsigargin | 1 | 1994 | 55 | 0.010 |
Why?
|
Glial Fibrillary Acidic Protein | 1 | 1994 | 58 | 0.010 |
Why?
|
Macromolecular Substances | 1 | 1994 | 176 | 0.010 |
Why?
|
Nicotine | 1 | 1995 | 199 | 0.010 |
Why?
|
DNA Primers | 1 | 1994 | 544 | 0.010 |
Why?
|
Receptors, Cell Surface | 1 | 1993 | 289 | 0.010 |
Why?
|
Ruthenium Red | 1 | 1990 | 2 | 0.010 |
Why?
|
Barium | 1 | 1990 | 31 | 0.010 |
Why?
|
Base Sequence | 1 | 1994 | 2333 | 0.010 |
Why?
|
Molecular Sequence Data | 1 | 1994 | 3028 | 0.010 |
Why?
|